ammonium (+)-10-camphorsulfonate | 83846-91-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: ammonium (+)-10-camphorsulfonate
• 英文别名: ammonium d-camphor-10-sulfonate；10-camphorsulfonate ammonium；camphor sulfonate ammonium；Azane;(7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl)methanesulfonic acid
• CAS: 83846-91-7
• 化学式: C₁₀H₁₅O₄S*H₄N
• mdl: MFCD10039754
• 分子量: 249.331
• InChiKey: JTMZBRWRXFAITF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.98
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  83.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ammonium (+)-10-camphorsulfonate 在 氯化铵 、 异丙醇 、 甲苯 作用下， 以 isopropanol hydrochloride 为溶剂， 反应 4.0h， 以to obtain 148 gm fresh camphor sulphonic acid的产率得到混旋樟脑磺酸
  参考文献：
  名称：

  PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I

  摘要：

  本发明描述了一种改进的工业过程，用于从类型1溶剂或具有两个或多个官能团或其混合物的液体中结晶出(+)氢硫酸氯吡格雷(也称为双硫酸氯吡格雷)的多晶形式I；或者从甲基乙酮、环戊甲基醚、二丙基乙二醇醚、二丁基乙二醇醚、丙基甲基纤维素醚、丁基甲基纤维素醚、丙基乙基纤维素醚、丁基乙基纤维素醚或它们的交叉组合中选择的类型II溶剂和/或溶剂混合物中以可重复的方式结晶，并且不会有多晶形式II的可检测污染。本发明还揭示了氯吡格雷游离碱的制备改进以及解析剂樟脑磺酸的回收和再利用过程。

  公开号：

  US20100081839A1

文献信息

• [EN] BENZOYLGLYCINE DERIVATIVES AND METHODS OF MAKING AND USING SAME<br/>[FR] DÉRIVÉS DE BENZOYLGLYCINE ET PROCÉDÉS DE PRODUCTION ET D'UTILISATION DE CES DÉRIVÉS
  申请人：UNIV DUKE

  公开号：WO2017189586A1

  公开（公告）日：2017-11-02

  Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1,R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.

  揭示了以下化合物及其药用盐，其中变量R1、R2、R3、R4、R5、R6、R7、R11、R12、R13、R14、R15、R16、R17、n和m在此处定义。这些化合物对治疗革兰氏阴性细菌感染有用。还公开了制备这些化合物的方法。
• [EN] EP2 RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RECEPTEUR EP2
  申请人：PHARMAGENE LAB LTD

  公开号：WO2005061449A1

  公开（公告）日：2005-07-07

  A compound selected from Formula (iv) or Formula (iii); (iv) (1R,2S)-2[4-1(S)-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid [RSS] or (iii) (1R,2S)-2[4-1(R)-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid [RSR] or a salt, solvate, chemically protected form or prodrug thereof, and its use in treating conditions alleviated by agonism of an EP2 receptor.

  从公式（iv）或公式（iii）中选择的化合物；（iv）（1R,2S）-2-[4-1（S）-羟基己基）苯基]-5-氧代环戊酰基庚酸[ RSS]或（iii）（1R,2S）-2-[4-1（R）-羟基己基）苯基]-5-氧代环戊酰基庚酸[ RSR]或其盐、溶剂合物、化学保护形式或前药，以及其在治疗通过EP2受体激动而缓解的病症中的应用。
• Reactive Extraction of Free Organic Acids from the Ammonium Salts Thereof
  申请人：Kobler Christoph

  公开号：US20100210871A1

  公开（公告）日：2010-08-19

  The invention relates to a process for converting ammonium salts of organic acids to the particular free organic acid, wherein an aqueous solution of the ammonium salt is contacted with an organic extractant and the salt is dissociated at temperatures and pressures at which the aqueous solution and the extractant are in the liquid state, and a stripping medium or entraining gas is introduced in order to remove NH 3 from the aqueous solution and transfer at least a portion of the free organic acid formed to the organic extractant. The invention described here thus provides an improved process for releasing an organic acid, preferably a carboxylic, sulphonic or phosphonic acid, especially an alpha-hydroxycarboxylic acid or beta-hydroxycarboxylic acid, from the ammonium salt thereof by release and removal of ammonia and simultaneous extraction of the acid released with a suitable extractant from the aqueous phase. This process corresponds to a reactive extraction. The reactive extraction of an organic acid from the aqueous ammonium salt solution thereof can be improved significantly by the use of a stripping medium or entraining gas, for example nitrogen, air, steam or inert gases, for example argon. The ammonia released is removed from the aqueous solution by the continuous gas stream and can be fed back into a production process. The free acid can be obtained from the extractant by a process such as distillation, rectification, crystallization, re-extraction, chromatography, adsorption, or by a membrane process.

  该发明涉及一种将有机酸铵盐转化为特定游离有机酸的过程，其中将铵盐的水溶液与有机萃取剂接触，并在水溶液和萃取剂处于液态的温度和压力下解离盐，并引入脱氨介质或夹带气体，以从水溶液中去除NH3并将形成的至少一部分游离有机酸转移到有机萃取剂中。该发明描述了一种改进的释放有机酸的过程，尤其是从铵盐中释放和去除氨并同时用适当的萃取剂从水相中萃取释放的酸，优选为羧酸、磺酸或膦酸，特别是α-羟基羧酸或β-羟基羧酸。这个过程对应于反应性萃取。通过使用脱氨介质或夹带气体（例如氮气、空气、蒸汽或惰性气体，例如氩气），可以显著改善从水溶液中的有机酸铵盐溶液中反应性萃取有机酸的过程。释放的氨由连续气流从水溶液中去除，并可以回馈到生产过程中。游离酸可以通过蒸馏、精馏、结晶、再萃取、色谱、吸附或膜过程等过程从萃取剂中获得。
• Therapeutic agent for Abeta related disorders
  申请人：Watanabe Hideki

  公开号：US20060241038A1

  公开（公告）日：2006-10-26

  The present invention provides a pharmaceutical composition comprising at least one member selected from a compound capable of enhancing Aβ37 production, a compound capable of inhibiting Aβ40 and Aβ42 production and enhancing Aβ37 production, and salts of the compounds and hydrates thereof.

  本发明提供了一种药物组合物，包括至少一种从能够增强Aβ37产生的化合物中选择的成员，一种能够抑制Aβ40和Aβ42产生并增强Aβ37产生的化合物，以及这些化合物的盐和水合物。
• EP2 receptor agonists
  申请人：Borman Anthony Richard

  公开号：US20050209336A1

  公开（公告）日：2005-09-22

  A compound selected from one of the following: or a salt, solvate, chemically protected form or prodrug thereof, and its use in treating conditions alleviated by agonism of an EP 2 receptor.

  从以下其中一种选择的化合物：或其盐，溶剂合物，化学保护形式或前药，以及其在治疗通过EP2受体激动而缓解的疾病中的使用。